Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
Holders of 5% or more of GBT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Global Blood Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Global Blood Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Global Blood Therapeutics, Inc., newest first.
No Schedule 13D or 13G filings on Global Blood Therapeutics, Inc. are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Global Blood Therapeutics, Inc. shares.
No Form 144 notices for Global Blood Therapeutics, Inc. are on file.